Ton Adang
Corporate Officer/Principal bei LAVA THERAPEUTICS N.V.
Vermögen: 2 112 $ am 30.04.2024
Profil
Ton Adang currently works at LAVA Therapeutics NV, as Chief Development Officer from 2017.
Dr. Adang also formerly worked at Merck KGaA, as Senior Director-Project & Pipeline Management from 2009 to 2010, AM-Pharma BV, as Project Director from 2014 to 2016, Fast Forward Pharmaceuticals BV, as Chief Operating Officer from 2012 to 2017, Simibio BV, as Chief Operating Officer from 2011 to 2014, and EnCare Biotech BV, as Chief Operating Officer from 2014 to 2017.
Dr. Adang received his doctorate degree in 1990 from the University of Leiden and graduate degree from Wageningen University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LAVA THERAPEUTICS NV
0,00% | 28.02.2023 | 800 ( 0,00% ) | 2 112 $ | 30.04.2024 |
Aktive Positionen von Ton Adang
| Unternehmen | Position | Beginn |
|---|---|---|
| LAVA THERAPEUTICS N.V. | Corporate Officer/Principal | 01.07.2017 |
Ehemalige bekannte Positionen von Ton Adang
| Unternehmen | Position | Ende |
|---|---|---|
EnCare Biotech BV
 EnCare Biotech BV Medical/Nursing ServicesHealth Services EnCare Biotech BV operates as a biopharmaceutical company which develops therapeutic antibody for the prevention of heart failure after acute myocardial infarction. Its product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin. The company was founded by Fatih Arslan in 2014 and is headquartered in Utrecht, the Netherlands. | Geschäftsführer | 01.12.2017 |
Fast Forward Pharmaceuticals BV
 Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Geschäftsführer | 01.10.2017 |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Corporate Officer/Principal | 01.09.2016 |
Simibio BV
 Simibio BV BiotechnologyHealth Technology Simibio BV develops therapeutic monoclonal antibodies. It serves the pharmaceutical industry. The company was founded in 2010 by Mark de Boer and is headquartered in Utrecht, the Netherlands. | Geschäftsführer | 01.06.2014 |
| MERCK KGAA | Corporate Officer/Principal | 01.03.2010 |
Ausbildung von Ton Adang
| University of Leiden | Doctorate Degree |
| Wageningen University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MERCK KGAA | Health Technology |
| LAVA THERAPEUTICS N.V. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
Fast Forward Pharmaceuticals BV
Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Health Technology |
Simibio BV
Simibio BV BiotechnologyHealth Technology Simibio BV develops therapeutic monoclonal antibodies. It serves the pharmaceutical industry. The company was founded in 2010 by Mark de Boer and is headquartered in Utrecht, the Netherlands. | Health Technology |
EnCare Biotech BV
EnCare Biotech BV Medical/Nursing ServicesHealth Services EnCare Biotech BV operates as a biopharmaceutical company which develops therapeutic antibody for the prevention of heart failure after acute myocardial infarction. Its product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin. The company was founded by Fatih Arslan in 2014 and is headquartered in Utrecht, the Netherlands. | Health Services |
